GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting 2-agonist indacaterol ( IND ) and the long-acting muscarinic antagonist glycopyrronium ( GLY ) versus IND alone in patients with moderate-to-severe COPD .